The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Open accessAbstract
Background & aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.Methods We fed foz/foz and wild-type mice an atherogenic diet for 16weeks, gavaged MCC950 or vehicle until 24weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6weeks and determined the effects on liver fibrosis.Results In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis.Conclusion MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.Lay summary Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [288]
The cited source says what the claim attributes to it.
In the citing paper
“Inflammasome activation is a hallmark of MASH livers (42)”
From Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2 (2024) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, while inhibition of inflammasome signaling, particularly NLRP3 activation in myeloid cells, demonstrated promising anti-fibrotic effects in murine models (142–144)”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [143]
In the citing paper
“Blockade of NLRP3 signaling with a small molecule inhibitor reduces disease severity in the MCD – Foz/Foz murine NASH model, although the relative contributions of targeting other inflammasome-expressing populations, including myeloid cells, have not been determined (77).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Self-citationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Self-citationInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Self-citationCusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 940
Cited by
Sorted by citations
Items 601–700 of 999
Kurtz, R., Anderman, M. F., & Shepard, B. D. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00275.2020 · Cited by 17
Gut microbiota in obesity and nonalcoholic fatty liver disease
Guo, L., Yang, K., Zhou, P., & Yong, W. (2021) · Surgery in Practice and Science · doi:10.1016/j.sipas.2021.100030 · Cited by 18
Wang, Y., Li, X., Chen, Q., Jiao, F., Shi, C., Pei, M., Wang, L.-W., & Gong, Z. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27114 · Cited by 16
Chen, H. H., Qiao, H., Zhao, Q., & Wei, F. (2022) · Bioengineered · doi:10.1080/21655979.2021.2024956 · Cited by 16
Kano, N., Ong, G. H., Ori, D., & Kawai, T. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.910654 · Cited by 20
Xiang, R., Liu, Y., Fan, L., Jiang, B., & Wang, F. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00805-8 · Cited by 16
20(S)-Protopanaxatriol ameliorates MAFLD by inhibiting NLRP3 inflammasome
Lu, B., Wang, D., Xie, D., Wu, C., & Sun, M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175468 · Cited by 17
Luo, Y., Jiao, Q., & Chen, Y. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2170780 · Cited by 16
Inia, J. A., Stokman, G., Pieterman, E. J., Morrison, M. C., Menke, A. L., Verschuren, L., Caspers, M. P. M., Giera, M. A., Jukema, J. W., van den Hoek, A. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097818 · Cited by 21
Li, Z., Ouyang, H., & Zhu, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1195146 · Cited by 16
Negro, R., Mastrogiacomo, R., Carrieri, L., Rizzi, F. R., Arrè, V., Minervini, G., Fanizza, E., Bianco, G., Panniello, A., Striccoli, M., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c04206 · Cited by 16
Barrón‐Cabrera, E., Soria-Rodriguez, R. A., Amador-Lara, F., & Martínez‐López, E. (2023) · Healthcare · doi:10.3390/healthcare11141992 · Cited by 18
Liu, H., Yeung, W. H., Pang, L., Liu, J., Liu, X. B., Ng, T., Zhang, Q., Qiu, W. Q., Zhu, Y., Ding, T., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100895 · Cited by 16
Abdurehman, D., Guoruoluo, Y., Lu, X.-Y., Li, J., Abudulla, R., Liu, G.-Y., Xin, X., & Aisa, H. (2023) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2023.115590 · Cited by 14
Ogawa, E., Suzuki, N., Kamiya, T., & Hara, H. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.23-16 · Cited by 17
Gruzdev, S., Podoprigora, I. V., & Gizinger, O. A. (2024) · Archives of Microbiology · doi:10.1007/s00203-023-03752-0 · Cited by 17
Nutrients and Immunometabolism: Role of Macrophage NLRP3
Larson, K., Alvine, T., Wu, D., Kalupahana, N. S., Moustaïd‐Moussa, N., & Roemmich, J. N. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa085 · Cited by 16
Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity
Luther, J., Gala, M. K., Borren, N. Z., Masia, R., Goodman, R. P., Moeller, I. H., DiGiacomo, E., Ehrlich, A. C., Warren, A., Yarmush, M. L., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1179 · Cited by 16
Inflammasomes as the molecular hub of cardiovascular-metabolic-immune comorbidity networks
Qian, X., Sun, J. M., Li, F., Li, X., Hu, X., Dong, N., & Li, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690443 · Cited by 18
Aurantio-obtusin induces hepatotoxicity through activation of NLRP3 inflammasome signaling
Hu, M., Li, L., Liu, J., Zhong, Y., Liang, B., Huang, Y., Li, Z., Lin, X., Wang, B., Zhang, B., et al. (2021) · Toxicology Letters · doi:10.1016/j.toxlet.2021.10.011 · Cited by 15
Yan, W., Shen, Y., Huang, J., Lü, L., & Zhang, Q. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.752223 · Cited by 15
Zhang, G., Tang, L., Liu, H., Liu, D., Wang, M., Cai, J., Liu, W., Nie, W., Zhang, Y., & Yu, X. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500944 · Cited by 15
Global research trends in atherosclerosis: A bibliometric and visualized study
Tian, W., Zhang, T., Wang, X., Zhang, J., Ju, J., & Xu, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.956482 · Cited by 18
Khanmohammadi, S., Ramos‐Molina, B., & Kuchay, M. S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102788 · Cited by 15
Chang, H., Yang, F., Bai, H., Lu, Z., Xing, C., Dai, X., Wan, W., Liao, S., & Cao, H. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110617 · Cited by 15
Zhou, Y., Yang, Z., Ou, Y., Cai, H., Liu, Z., Lin, G., Liang, S., Hua, L., Yan, Y., Zhang, X., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04881-x · Cited by 15
Meng, Z., Zhou, L., Hong, S., Qiu, X., Chen, Z., Liu, T., Inoki, K., & Lin, J. D. (2023) · Hepatology · doi:10.1097/hep.0000000000000537 · Cited by 16
Chen, M., Huang, F., Chen, B., Kang, J., Yao, Y., Liu, M., Li, Y., Li, Y., Zhou, T., Peng, D., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115831 · Cited by 15
Tan, X., Yi, L., Zhang, R., Zhang, Y., You, Z., & Yang, L. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300912 · Cited by 16
Vallée, D., Blanc, M., Lebeaupin, C., & Bailly‐Maitre, B. (2020) · médecine/sciences · doi:10.1051/medsci/2020008 · Cited by 16
Molecular Hydrogen as a Novel Protective Agent against Pre-Symptomatic Diseases
Yamamoto, H., Ichikawa, Y., Hirano, S., Sato, B., Takefuji, Y., & Satoh, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137211 · Cited by 17
Resveratrol ameliorates nutritional steatohepatitis through the mmu‑miR‑599/PXR pathway
Kong, L., An, X. Y., Hu, L., Zhang, S., Liu, L., Zhao, S., Wang, R., & Nan, Y. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5102 · Cited by 15
Vargas-Pozada, E. E., Ramos‐Tovar, E., Rodríguez-Callejas, J. D., Cardoso-Lezama, I., Galindo‐Gómez, S., Gil-Becerril, K. M., Vásquez-Garzón, V. R., Arellanes‐Robledo, J., Tsutsumi, V., Villa‐Treviño, S., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100780 · Cited by 15
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 17
Chen, F., Liu, Y., Li, Q., & Wang, F. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102056 · Cited by 14
Zhu, K., Wu, M., Bian, Z.-L., Han, S.-L., Fang, L., Ge, F., Wang, X.-Z., & Xie, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1293468 · Cited by 16
Pucinelli, C. M., da Silva, R. A. B., Nelson‐Filho, P., Lima, R. B., Lucisano, M. P., Marchesan, J. T., & da Silva, L. A. B. (2024) · Clinical Oral Investigations · doi:10.1007/s00784-024-05691-6 · Cited by 14
Mohammed, D. M., Salem, M. B., Elzallat, M., Hammam, O. A., & Suliman, A. A. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104286 · Cited by 14
Zhang, Y.-T. Y., Guo, S., Fu, X., Zhang, Q., & Wang, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112342 · Cited by 16
Chen, H., Zhang, J., Chen, X.-Q., Luo, L., Dong, W.-J., Wang, Y.-J., Zhou, J., Chen, C.-J., Wang, W.-H., Zhang, W., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1449064 · Cited by 17
Immune Checkpoints and the Immunology of Liver Fibrosis
Tsomidis, I., Voumvouraki, A., & Kouroumalis, E. (2025) · Livers · doi:10.3390/livers5010005 · Cited by 14
Wang, H., Zhang, S., Zhao, H., Qin, H., Zhang, J., Dong, J., Zhang, H., Liu, X., Zhao, Z., Zhao, Y., et al. (2020) · Medical Science Monitor · doi:10.12659/msm.920668 · Cited by 14
Characterization of a common carp intelectin gene with bacterial binding and agglutination activity
Li, J., Chen, Y., Gu, W., Xu, F., Li, H., Shan, S., Sun, X., Yin, M., Yang, G., & Chen, L. (2020) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2020.11.025 · Cited by 14
Sim, J. H., Sherman, J. B., Stanley, T. L., Corey, K. E., Fitch, K. V., Looby, S. E. D., Robinson, J. A., Lu, M. T., Burdo, T. H., & Lo, J. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0177 · Cited by 14
NLRP3 as a sensor of metabolism gone awry
Neuwirt, E., Gorka, O., Saller, B. S., Groß, C. J., Madl, T., & Groß, O. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.03.009 · Cited by 13
Dadmanesh, M., Ranjbar, M. M., & Ghorban, K. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.001 · Cited by 14
Gut microbiome-specific nanoparticle-based therapeutics for liver diseases
Khurana, A., & Hartmann, P. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i27.109105 · Cited by 14
Park, J., Lee, M., Seo, Y., Kang, B., Lim, S., & Kang, K. W. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120127 · Cited by 13
Hepatic Myofibroblasts: A Heterogeneous and Redox-Modulated Cell Population in Liver Fibrogenesis
Bocca, C., Protopapa, F., Foglia, B., Maggiora, M., Cannito, S., Parola, M., & Novo, E. (2022) · Antioxidants · doi:10.3390/antiox11071278 · Cited by 14
Hu, P., Sheng, M.-Y., Liu, Y.-P., & Zhang, C. (2022) · Human Cell · doi:10.1007/s13577-022-00760-y · Cited by 13
Subramanian, P., & Chavakis, T. (2023) · The Journal of Physiology · doi:10.1113/jp283820 · Cited by 13
Tao, H., Liu, Q., Zeng, A., & Song, L. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110497 · Cited by 13
Healthy diet intervention reverses the progression of NASH through gut microbiota modulation
Panyod, S., Wu, W., Hu, M.-Y., Huang, H., Chen, R.-A., Chen, Y., Shen, T. D., Ho, C., Liu, C., Chuang, H.-L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01868-23 · Cited by 14
Kim, M., Jeong, B., Lee, G., Jeon, H., Yang, Y. M., Yang, H. J., & Han, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111565 · Cited by 13
Chang, E. (2024) · Molecules · doi:10.3390/molecules29061401 · Cited by 19
Yang, Y., & Wang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419384 · Cited by 15
Liver Macrophage Diversity in Health and Disease
Horn, P., & Tacke, F. (2024) · Results and problems in cell differentiation · doi:10.1007/978-3-031-65944-7_7 · Cited by 14
Liu, Y., Wang, Q., Ma, J., Li, J., Li, C., Xie, X., Xiao, Q., Xie, C., Liu, H. S., Hong, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02813 · Cited by 13
Wang, Z., Liu, J., Mou, Y., Zhou, X., Liao, W., Li, Y., Liu, Y., & Tang, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156904 · Cited by 14
Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo
Xiang, C., Chen, X., Yao, J., Yang, N., Yu, J., Qiu, Q., Zhang, S., Kong, X., Zhao, L., Fan, Z., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115510 · Cited by 13
Wang, Y., Shi, C., Guo, J., Zhang, Y., & Gong, Z. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00132 · Cited by 13
Loss of NLRP3 Function Alleviates Murine Hepatic Graft-versus-Host Disease
Zhu, S., Shi, P., Lv, C., Li, H., Pan, B., Chen, W., Zhao, K., Yan, Z., Chen, C., Loake, G. J., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.07.026 · Cited by 13
Zhu, L., Liu, C., Li, Z.-R., Niu, C., & Wu, J. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00535-3 · Cited by 13
Liu, J., Wang, T., Yang, F., & Pubu, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1642436 · Cited by 13
Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
Kalo, E., Read, S. A., & Ahlenstiel, G. (2021) · Livers · doi:10.3390/livers1030014 · Cited by 12
Sustained activation of NLRP3 inflammasome contributes to delayed wound healing in aged mice
Li, H., Wang, Z., Zhou, F., Zhang, G., Feng, X., Xiong, Y., & Wu, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109828 · Cited by 12
Xu, X., Feng, J., Wang, X., Zeng, X., Luo, Y., He, X., Yang, M., Lv, T., Feng, Z., Bao, L., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00562 · Cited by 12
Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
Ni, K., & Meng, L. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102381 · Cited by 14
Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases
Usman, I., Anwar, A., Shukla, S., & Pathak, P. (2024) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x310857240607103028 · Cited by 12
He, F., Du, W., Liu, Y., Ling, Y., Xu, M. J., Liu, J., Song, P., Fang, Z., Yue, Z., Duan, J., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103488 · Cited by 13
Xu, Z.-X., Tang, C., Song, X., Liu, Z.-N., Zhou, J., Shi, Q., Yu, C.-H., & Xu, C. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110249 · Cited by 14
Reviewing the function of macrophages in liver disease
Chen, L., Guillot, A., & Tacke, F. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2508963 · Cited by 15
Emerging therapeutic targets for NASH: key innovations at the preclinical level
Horn, P., & Newsome, P. N. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1728742 · Cited by 12
Yang, R., Jia, Q., Li, Y., & Mehmood, S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220931038 · Cited by 12
Li, Y., Zhao, J., Wu, Y., & Xia, L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.094 · Cited by 12
He, X., Hu, Y., Liu, W., Zhu, G., Zhang, R., You, J., Shao, Y., Li, Y., Zhang, Z., Cui, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.818227 · Cited by 12
MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure
Jiang, X., Yang, F., Ou, D., Huang, L., Li, H., & Lang, M. (2022) · Bioengineered · doi:10.1080/21655979.2022.2053813 · Cited by 13
Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction
Ahmad, R., & Haque, M. (2022) · Vaccines · doi:10.3390/vaccines10040614 · Cited by 14
Liu, C., Chen, K., Zhao, F., Xuan, L., Wang, Y., Xu, C., Wu, Z., Wang, D., & Qu, C. (2022) · BMC Medicine · doi:10.1186/s12916-022-02481-3 · Cited by 12
Zhao, R., Zhao, H., Guo, Q., Mu, Y., Zhang, J., Su, Y., & Han, Q. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110251 · Cited by 12
Aggan, H. E., Mahmoud, S., Deeb, N. E., Eleishi, I., & El-Shendidi, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-22022-5 · Cited by 12
Sekiguchi, Y., Takano, S., Noguchi, T., Kagi, T., Komatsu, R., Tan, M., Hirata, Y., & Matsuzawa, A. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200611 · Cited by 12
Choi, J.-H., Cho, Y. S., Choi, H., Lee, S., Han, H.-J., Lee, J., & Kwon, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043439 · Cited by 12
Saha, S., Ray, S., Mandal, A., Das, U. B., Bhattacharya, T., Shireen, Z., Sarkar, S., Sharma, R. D., Ghosh, S., & Dey, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121911 · Cited by 12
Kim, K., & Kim, K. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072296 · Cited by 13
Lamadrid, P., Alonso‐Peña, M., Segundo, D. S., Arias, M., Crespo, J., & López‐Hoyos, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651728 · Cited by 12
Clonal hematopoiesis and risk of chronic liver diseasePreprint
Wong, W. J., Emdin, C. A., Bick, A. G., Zekavat, S. M., Niroula, A., Pirruccello, J. P., Dichtel, L. E., Griffin, G. K., Uddin, M. M., Gibson, C. J., et al. (2022) · medRxiv · doi:10.1101/2022.01.17.22269409 · Cited by 12
Yin, J., Zhu, Y., Liu, R., Wang, W., Wang, Z., & Wang, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599956 · Cited by 12
Tang, X., Zhou, Y., Xia, L., Lin, X., Zhu, Y., Chen, M., Wang, J., & Li, Y. (2025) · Molecules · doi:10.3390/molecules30153066 · Cited by 11
Co-expression of fibrotic genes in inflammatory bowel disease; A localized event?
Dovrolis, N., Filidou, E., Tarapatzi, G., Kokkotis, G., Spathakis, M., Kandilogiannakis, L., Drygiannakis, I., Valatas, V., Arvanitidis, K. I., Karakasiliοtis, I., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058237 · Cited by 11
The role of the canonical nf-κb signaling pathway in the development of acute liver failure
Li, H., Niu, X., Zhang, D., Qu, M., & Yang, K. (2022) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2022.2162999 · Cited by 12
Kunte, S. C., Marschner, J. A., Klaus, M., Honda, T. S. B., Li, C., Motrapu, M., Walz, C., Angelotti, M. L., Antonelli, G., Melica, M. E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1230050 · Cited by 11
Qu, H., Zhang, D., Liu, J., Deng, J., Xie, R., Zhang, K., Li, H., Tao, P., Wang, G., Sun, J. L., et al. (2024) · Engineering · doi:10.1016/j.eng.2024.05.005 · Cited by 10
Li, S., Liu, A.-B., Yu, Y., & Ma, J.-H. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1407738 · Cited by 12
Zhu, W., Bao, X., Yang, Y., Xing, M., Xiong, S., Chen, S., Zhong, Y., Hu, X., Lu, Q. R., Wang, K., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02648 · Cited by 13
Jia, H., Li, J., Chen, X., Liu, Z., Wu, C., Liu, C., Zhang, J., Luo, M., Huang, M., Huang, S., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156489 · Cited by 11
Kim, D.-H., Choi, G. H., Song, E.-B., Lee, H. N., Kim, J. K., Jang, Y., Park, J., Chi, S., Han, J., Kim, D., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102047 · Cited by 11
Ogawa, M., Kanda, T., Higuchi, T., Takahashi, H., Kaneko, T., Matsumoto, N., Nirei, K., Yamagami, H., Matsuoka, S., Kuroda, K., et al. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.34245 · Cited by 11
Chen, J., Yang, F., Shi, S., Liu, X., Qin, F., Wei, X., Huang, Y., Liang, W., & Miao, L. (2021) · Mediators of Inflammation · doi:10.1155/2021/5551578 · Cited by 12
Xing, Z., Yayun, W., & Liu, N. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10522 · Cited by 11
Metadata
- Authors
- Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., Masters, S. L., Schroder, K., Cooper, M. A., Feldstein, A. E., & Farrell, G. C.
- Affiliations
- Australian National University (AU)
- University of California San Diego (US)
- The University of Queensland (AU)
- University of Washington (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Farrell, Geoffrey C.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 66
- Issue
- 5
- Pages
- 1037-1046
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC6536116
- OpenAlex
- W2585046292
- Cited by
- 1,110
- References
- 49
- Citations by year
- 2026: 117 · 2025: 147 · 2024: 126 · 2023: 150 · 2022: 160 · 2021: 143 · 2020: 121 · 2019: 61 · 2018: 70 · 2017: 14
- FWCI
- 57.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- ANU Open Research (Australian National University) (submittedVersion, cc-by-nc-nd)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (U01AA022489, R21AA023574)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK113592)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- NLRP3 inflammasome, MCC950, nonalcoholic steatohepatitis, liver fibrosis, liver inflammation, IL-1β, caspase-1, cholesterol crystals, Kupffer cells, macrophages, neutrophil migration, methionine-choline-deficient diet, atherogenic diet, myeloid cells
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Disease Models, Animal, Female, Furans, Hepatitis, Heterocyclic Compounds, 4 or More Rings, Indenes, Liver Cirrhosis, Experimental, Sulfonamides, Sulfones, NF-kappa B, Reactive Oxygen Species, Mice, Interleukin-1beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
